Aclaris Therapeutics (ACRS)
Develops immunology drug candidates through biologics, kinase inhibitors, and discovery services.
Something off on this page? Send us feedback.
Develops immuno-inflammatory therapies around licensed biologics, oral kinase inhibitors, and the KINect discovery platform. Revenue comes from intellectual-property licensing and laboratory services while the main business remains clinical development rather than approved-product sales.
Focuses on immuno-inflammatory diseases with a clinical pipeline built around bosakitug, ATI-052, ATI-2138, ATI-9494, and KINect discovery work. The portfolio mixes licensed biologics with oral kinase inhibitors, while laboratory services and intellectual-property licensing provide the current revenue base.
Operates from Pennsylvania as a pre-commercial biotech without an owned commercial sales force. Earlier dermatology products such as ESKATA and RHOFADE gave way to a refocus on immunology research and partner-led development after the commercial dermatology buildout was discontinued.
Execution depends on clinical trial progress, third-party partners, and outside manufacturing for product candidates and trial materials. Competitive pressure comes from other immunology programs targeting overlapping pathways.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 1, 2026 | Canaccord Genuity | Target | Target: — | Target: $10 |
| May 5, 2026 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $11 |
| May 5, 2026 | Guggenheim | Target | Target: — | Target: $12 |
| Apr 29, 2026 | Wedbush | Reiterate | Rating: —Target: — | Target: $10 |
| Apr 16, 2026 | UBS | Target | Target: — | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $91.6M · Total debt $0 · Total assets $179.7M · Shareholders' equity $124.6M
- Revenue
- $1.6M
- Operating income
- −$24.2M
- Net income
- −$21.5M
No dividends on record.
| Institutions | ≈ 80.97% | 119.18M shares | |
|---|---|---|---|
| 156 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.18% | 3.21M shares | |
| 13 holders · as of Aug 4, 2026 | |||
| Strategic holders | 7.66% | 11.28M shares | |
| 1 holder · as of Jan 9, 2026 | |||
| Other | ≈ 9.19% | 13.52M shares | |
| remainder | |||
147.20M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BML Investment Partners, L.P.Institution | 9.48% | 13.95M | filed Apr 27, 2026 |
Ra Capital Management, L.P.Institution | 8.64% | 12.72M | as of Jun 30, 2026 |
BML Capital Management, LLCInstitution | 8.14% | 11.98M | as of Jun 30, 2026 |
Biosion, Inc.Strategic | 7.66% | 11.28M | filed Jan 9, 2026 |
BlackRock, Inc.Institution | 6.82% | 10.04M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard | 10 percent owner | −300,000 | $4.53 |
- Sanofi (ADR)
Dupixent and lunsekimig pressure type-2 immunology programs
- Pfizer
Type-2 trispecific antibodies plus marketed AD JAK exposure
- Regeneron
Dupixent co-owner with deep type-2 inflammation reach
- AstraZeneca (ADR)
Tezspire anchors approved anti-TSLP asthma competition
- Upstream Bio
Verekitug targets the TSLP receptor in respiratory disease
- Corvus Pharmaceuticals
Selective ITK inhibition overlaps ATI-2138 kinase strategy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics | $5.17 | −9.58% | $798.9M | — | — | 97.2 | −8.3% |
| Sanofi (ADR) | $41.61 | −2.12% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Pfizer | $28.04 | +0.38% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Regeneron | $792.48 | −1.42% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| AstraZeneca (ADR) | $164.51 | −2.30% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Upstream Bio | $5.19 | −5.50% | $298.8M | — | — | 94.6 | −17.5% |
| Corvus Pharmaceuticals | $12.59 | −6.32% | $1.13B | — | — | — | — |
| Median | 31.1 | 13.1 | 4.3 | +6.4% |